15908 Long-term efficacy and safety of brodalumab in patients with or without metabolic syndrome
Journal of The American Academy of Dermatology(2020)
Abstract
Background: We assessed the long-term efficacy and safety of brodalumab, a fully human anti–interleukin-17 receptor A monoclonal antibody, in patients with moderate to severe plaque psoriasis, stratified by baseline metabolic syndrome (MetSyn) status.
MoreTranslated text
Key words
brodalumab,metabolic,long-term
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined